Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Clinical trial NCT03220035 · COMPLETED

Trial details

NCT number: NCT03220035
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Malignant Solid Neoplasm Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell Histiocytosis Malignant Germ Cell Tumor Malignant Glioma Osteosarcoma Peripheral Primitive Neuroectodermal Tumor Recurrent Childhood Central Nervous System Neoplasm

Start date: 2017-11-08
Primary completion: 2022-06-30
Enrollment: 4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.